EICHORPublic-registry site landscape for NCT03568656, “Study to Evaluate CCS1477 in Advanced Tumours”, a Metastatic Castration-Resistant Prostate Cancer study sponsored by CellCentric Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03568656 (registry record) |
| Study title | Study to Evaluate CCS1477 in Advanced Tumours |
| Official title | An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours. |
| Sponsor | CellCentric Ltd. |
| Condition(s) | Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 19 |
| Site countries | United States, France, Netherlands, Spain, Sweden, United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT03568656.
Eichor generates a preliminary site-risk snapshot for NCT03568656 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Metastatic Castration-Resistant Prostate Cancer trials
← Eichor home · All tracked trials · Metastatic Castration-Resistant Prostate Cancer studies · Weekly briefs
